Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
作者信息
Tacchetti Paola, Pezzi Annalisa, Zamagni Elena, Pantani Lucia, Rocchi Serena, Zannetti Beatrice Anna, Mancuso Katia, Rizzello Ilaria, Cavo Michele
机构信息
"Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
"Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy
出版信息
Haematologica. 2017 Mar;102(3):e104-e107. doi: 10.3324/haematol.2016.154070. Epub 2016 Dec 1.
Abstract
摘要
相似文献
1
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.血清游离轻链检测在接受新型药物一线治疗的多发性骨髓瘤患者早期复发检测及复发后预后预测中的作用
Haematologica. 2017 Mar;102(3):e104-e107. doi: 10.3324/haematol.2016.154070. Epub 2016 Dec 1.
2
Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.基于多中心患者的游离轻链比值正常化在多发性骨髓瘤疾病复发中作用的证据
Eur J Haematol. 2016 Feb;96(2):119-27. doi: 10.1111/ejh.12556. Epub 2015 Apr 21.
3
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.外泌体相关微小RNA谱及体内环境在预测多发性骨髓瘤患者耐药性中的潜在作用
Oncotarget. 2016 May 24;7(21):30876-91. doi: 10.18632/oncotarget.9021.
4
Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.监测接受自体干细胞移植的多发性骨髓瘤患者血清游离轻链的早期预后价值
Cancer Invest. 2017 Mar 16;35(3):195-201. doi: 10.1080/07357907.2016.1270958. Epub 2017 Jan 23.
5
Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.受累/未受累重/轻链指数可预测移植后多发性骨髓瘤患者的病情进展。
Bone Marrow Transplant. 2017 Aug;52(8):1206-1207. doi: 10.1038/bmt.2017.97. Epub 2017 Jun 5.
6
Response evaluation and monitoring of multiple myeloma.多发性骨髓瘤的疗效评估与监测
Expert Rev Hematol. 2014 Feb;7(1):33-42. doi: 10.1586/17474086.2014.876899.
7
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.多发性骨髓瘤的新复发模式：“轻链逃逸”病例，其中 FLC 比尿液和血清免疫固定化更早预测复发。
Clin Chem Lab Med. 2016 Jun 1;54(6):991-5. doi: 10.1515/cclm-2015-0689.
8
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.循环中血管细胞黏附分子-1（VCAM-1）水平升高与多发性骨髓瘤患者的疾病进展及不良生存相关：硼替佐米和来那度胺治疗后其水平降低
Blood Cancer J. 2016 May 27;6(5):e428. doi: 10.1038/bcj.2016.37.
9
Multiple myeloma: is a shift toward continuous therapy needed to move forward?多发性骨髓瘤：是否需要转向持续治疗以取得进展？
Expert Rev Hematol. 2015 Jun;8(3):253-6. doi: 10.1586/17474086.2015.1001360. Epub 2015 Jan 12.
10
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.冒烟型多发性骨髓瘤的变化态势：欧洲视角
Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26.
引用本文的文献
1
A Bayesian Joint Model of Multiple Nonlinear Longitudinal and Competing Risks Outcomes for Dynamic Prediction in Multiple Myeloma: Joint Estimation and Corrected Two-Stage Approaches.用于多发性骨髓瘤动态预测的多个非线性纵向和竞争风险结果的贝叶斯联合模型：联合估计和校正两阶段方法
Stat Med. 2025 Feb 10;44(3-4):e10322. doi: 10.1002/sim.10322.
2
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.血清游离轻链检测在免疫球蛋白分泌型多发性骨髓瘤中的反应和进展中的作用。
Am J Hematol. 2022 Dec;97(12):1607-1615. doi: 10.1002/ajh.26747. Epub 2022 Oct 18.
3
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.在GMMG-MM5试验中接受治疗的多发性骨髓瘤患者中，血清游离轻链比值正常化的预后影响
Cancers (Basel). 2021 Sep 28;13(19):4856. doi: 10.3390/cancers13194856.
4
Prognostic and predictive biomarker developments in multiple myeloma.多发性骨髓瘤的预后和预测生物标志物的发展。
J Hematol Oncol. 2021 Sep 23;14(1):151. doi: 10.1186/s13045-021-01162-7.
5
Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy.基于抗CD38治疗前，复发/难治性多发性骨髓瘤患者中FDG-PET/CT参数的预后价值
Cancers (Basel). 2021 Aug 27;13(17):4323. doi: 10.3390/cancers13174323.
6
Serum free light chains and multiple myeloma: Is it time to extend their application?血清游离轻链与多发性骨髓瘤：是时候拓展其应用范围了吗？
Clin Case Rep. 2020 Mar 6;8(4):617-624. doi: 10.1002/ccr3.2636. eCollection 2020 Apr.
本文引用的文献
1
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.在接受基于硼替佐米方案治疗的新诊断多发性骨髓瘤病程中，血清游离轻链检测系列测量的预后影响。
Leuk Lymphoma. 2016 Sep;57(9):2058-64. doi: 10.3109/10428194.2015.1124994. Epub 2016 Jan 14.
2
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.血清游离轻链与尿液电泳在检测轻链型和完整免疫球蛋白型多发性骨髓瘤中单克隆免疫球蛋白轻链成分方面的比较。
Haematologica. 2016 Mar;101(3):356-62. doi: 10.3324/haematol.2015.126797. Epub 2015 Dec 3.
3
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.血清游离免疫球蛋白轻链评估作为克隆内异质性对骨髓瘤预后影响的标志物。
Blood. 2014 May 29;123(22):3414-9. doi: 10.1182/blood-2013-12-542662. Epub 2014 Apr 14.
4
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.血清游离轻链比值作为高危冒烟型多发性骨髓瘤的生物标志物。
Leukemia. 2013 Apr;27(4):941-6. doi: 10.1038/leu.2012.296. Epub 2012 Oct 16.
5
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.统一临床试验报告的共识建议：国际骨髓瘤工作组共识小组报告 1.
Blood. 2011 May 5;117(18):4691-5. doi: 10.1182/blood-2010-10-299487. Epub 2011 Feb 3.
6
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.国际骨髓瘤工作组关于多发性骨髓瘤及相关疾病血清游离轻链分析的指南。
Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20.
7
'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.“轻链逃逸-多发性骨髓瘤”——一种来自平台期的逃逸现象：使用轻链监测的最大患者系列报告
J Cancer Res Clin Oncol. 2009 Mar;135(3):477-84. doi: 10.1007/s00432-008-0470-7. Epub 2008 Sep 18.
8
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.血清游离轻链比值在新诊断骨髓瘤中的预后价值：建议纳入国际分期系统。
Leukemia. 2008 Oct;22(10):1933-7. doi: 10.1038/leu.2008.171. Epub 2008 Jul 3.
9
International uniform response criteria for multiple myeloma.多发性骨髓瘤的国际统一反应标准。
Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20.
10
Serum free light chains for monitoring multiple myeloma.用于监测多发性骨髓瘤的血清游离轻链
Br J Haematol. 2004 Aug;126(3):348-54. doi: 10.1111/j.1365-2141.2004.05045.x.
Zotero 插件